← Back to Clinical Trials
Recruiting NCT03238690

NCT03238690 LVAD Conditioning for Cardiac Recovery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03238690
Status Recruiting
Phase
Sponsor STAVROS G DRAKOS
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2017-06-23
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Controlled Cardiac Reloading through LVAD Speed Adjustment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2017-06-23 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to investigate the potential recovery of heart function in end-stage heart failure patients supported with a Left Ventricular Assist Device (LVAD) through applying a myocardial conditioning protocol. During myocardial conditioning, LVAD speed is reduced gradually in order to increase the work load of the heart. Multiple previous studies have shown that interventions like this may improve heart function and give patients the opportunity for a better quality of life.

Eligibility Criteria

Inclusion Criteria: * Diagnosed with heart failure undergoing LVAD implantation as a bridge to transplant * Enrolled in the Effects of Mechanical Unloading on Myocardial Function and Structure study (IRB 30622) Exclusion Criteria: * Neither the subject nor the subject's representative is willing to provide written consent for participation * Subjects with adverse events leading to hospitalization during the optimum unloading phase are excluded from participation in the controlled reloading phase

Contact & Investigator

Central Contact

John Kirk

✉ john.kirk@hsc.utah.edu

📞 801-585-2944

Principal Investigator

Stavros Drakos, MD

PRINCIPAL INVESTIGATOR

University of Utah

Frequently Asked Questions

Who can join the NCT03238690 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03238690 currently recruiting?

Yes, NCT03238690 is actively recruiting participants. Contact the research team at john.kirk@hsc.utah.edu for enrollment information.

Where is the NCT03238690 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT03238690 clinical trial?

NCT03238690 is sponsored by STAVROS G DRAKOS. The principal investigator is Stavros Drakos, MD at University of Utah. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology